A Bacterial Protein as the First True Antidote for Carbon Monoxide Poisoning

The Silent Killer and a New Hope

Carbon monoxide, often referred to as the “silent killer,” poses a significant threat to public health. Each year, approximately 50,000 Americans are rushed to emergency rooms due to exposure to this invisible gas, with around 1,500 fatalities reported annually. The danger lies in its ability to go undetected, making it particularly deadly. Current treatment methods have remained largely unchanged for decades, with doctors typically administering oxygen, sometimes through high-pressure chambers, hoping for recovery. Unfortunately, nearly half of the survivors experience long-term damage to the brain or heart.

A groundbreaking development from a collaborative effort between the University of Maryland School of Medicine, the University of Pittsburgh, and Wake Forest University offers new hope. Scientists have created a protein-based antidote named RcoM-HBD-CCC that can rapidly remove carbon monoxide (CO) from the bloodstream. This innovative treatment stands out because it does not cause dangerous spikes in blood pressure, a common side effect of previous attempts.

How the Antidote Works

The therapy is inspired by a bacterium known as Paraburkholderia xenovorans, which naturally detects CO in its environment. The bacterial protein responsible for this detection, called RcoM, is highly sensitive to even trace amounts of the gas. Researchers modified this protein into a compact form, RcoM-HBD-CCC, which binds to CO with remarkable strength—nearly 50 times stronger than hemoglobin. Hemoglobin in red blood cells normally carries oxygen but can also bind to CO, reducing oxygen transport. However, RcoM-HBD-CCC's selectivity for CO over oxygen allows it to act like a molecular sponge, pulling CO off hemoglobin and allowing red blood cells to resume their oxygen-carrying function.

In experiments with mice, the antidote showed rapid effectiveness. After exposure to CO, treated animals experienced a much faster clearance of the gas from their blood compared to untreated ones. Additionally, the protein was safely excreted through urine, indicating a promising path for further development.

“This has the potential to become a rapid, intravenous antidote for carbon monoxide that could be given in the emergency department or even in the field by first-responders,” said study author Mark T. Gladwin, Dean of the University of Maryland School of Medicine.

Why This Approach Is Different

Previous attempts to develop CO scavengers have faced challenges, particularly with unintended interactions. Many engineered proteins, while effective at trapping CO, also bind to nitric oxide, a molecule that regulates blood pressure. This can lead to dangerous increases in blood pressure, kidney damage, or other complications.

However, RcoM-HBD-CCC appears to avoid these issues. Laboratory tests show that it reacts with nitric oxide much more slowly than other protein therapies. In mice, even at high doses, the protein did not cause hypertension or organ damage.

“This molecule could be a game-changer because it can directly and rapidly remove carbon monoxide from the body with such a low risk of off-target side effects,” said Jason J. Rose, Associate Professor of Medicine at UMSOM.

The team’s data reveal why: CO binds so tightly to the engineered protein that it rarely escapes. The half-life of CO inside the protein is measured in days, compared to minutes for oxygen. This one-way binding makes the protein highly effective.

What Comes Next

Currently, the therapy has only been tested in mice, and human trials are still years away. Researchers must address several critical questions: What is the appropriate dose? Can the protein work effectively in severely poisoned patients where damage may already be extensive? How will regulators assess a drug designed for emergency use rather than daily administration?

Beyond treating CO poisoning, the potential applications of similar molecules could extend to other medical fields. Rose suggests that such proteins might one day serve as blood substitutes for individuals with severe anemia or blood loss, or even help preserve organs before transplantation.

Despite these possibilities, the primary goal remains an effective antidote for carbon monoxide. For decades, emergency medicine has relied on oxygen tanks and hyperbaric chambers. If RcoM-HBD-CCC fulfills its promise, it could provide doctors and first responders with a tool that acts within minutes, rather than hours.